These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7804227)

  • 1. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin.
    Cama VA; Marshall MM; Shubitz LF; Ortega YR; Sterling CR
    J Eukaryot Microbiol; 1994; 41(5):25S. PubMed ID: 7804227
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice.
    Fayer R; Fetterer R
    J Parasitol; 1995 Oct; 81(5):794-5. PubMed ID: 7472880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice.
    Moore D; Waters WR; Wannemuehler MJ; Harp JA
    J Parasitol; 2001 Feb; 87(1):211-3. PubMed ID: 11227893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
    Morales Gomez MA
    Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous interleukin-12 (IL-12) exacerbates Cryptosporidium parvum infection in gamma interferon knockout mice.
    Smith LM; Bonafonte MT; Campbell LD; Mead JR
    Exp Parasitol; 2001 Jul; 98(3):123-33. PubMed ID: 11527435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice.
    Fayer R; Ellis W
    J Parasitol; 1993 Aug; 79(4):553-8. PubMed ID: 8392541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
    Rueda C; Fenoy S; Simón F; Del Aguila C
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum.
    Urban JF; Fayer R; Chen SJ; Gause WC; Gately MK; Finkelman FD
    J Immunol; 1996 Jan; 156(1):263-8. PubMed ID: 8598471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral dosing of neonatal mice with sucrose reduces infection with Cryptosporidium parvum.
    Harp JA
    J Parasitol; 1999 Oct; 85(5):952-5. PubMed ID: 10577733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against the early acute phase of Cryptosporidium parvum infection conferred by interleukin-4-induced expression of T helper 1 cytokines.
    McDonald SA; O'Grady JE; Bajaj-Elliott M; Notley CA; Alexander J; Brombacher F; McDonald V
    J Infect Dis; 2004 Sep; 190(5):1019-25. PubMed ID: 15295711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of an improved semiquantitative technique for detecting low-level Cryptosporidium parvum infections in mouse tissue using polymerase chain reaction.
    Jenkins MC; Trout J; Fayer R
    J Parasitol; 1998 Feb; 84(1):182-6. PubMed ID: 9488364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection dynamics of Cryptosporidium parvum in ICR outbred suckling mice.
    Upton SJ; Gillock HH
    Folia Parasitol (Praha); 1996; 43(2):101-6. PubMed ID: 8768460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of a prolonged C. parvum infection in immunocompetent adult C57BL/6 mice.
    Johansen GA; Sterling CR
    J Eukaryot Microbiol; 1994; 41(5):45S. PubMed ID: 7804244
    [No Abstract]   [Full Text] [Related]  

  • 14. Cryptosporidium parvum-induced inflammatory bowel disease of TCR-beta- x TCR-delta-deficient mice.
    Waters WR; Wannemuehler MJ; Sacco RE; Palmer MV; Haynes JS; Pesch BA; Harp JA
    J Parasitol; 1999 Dec; 85(6):1100-5. PubMed ID: 10647043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cryptosporidium parvum: an emerging threat to the man].
    Grzeszczuk A; Prokopowicz D
    Przegl Epidemiol; 1999; 53(3-4):345-53. PubMed ID: 10800573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dicationic furans inhibit development of Cryptosporidium parvum in HSD/ICR suckling Swiss mice.
    Blagburn BL; Drain KL; Land TM; Moore PH; Kinard RG; Lindsay DS; Kumar A; Shi J; Boykin DW; Tidwell RR
    J Parasitol; 1998 Aug; 84(4):851-6. PubMed ID: 9714224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplementation with Lactobacillus reuteri or L. acidophilus reduced intestinal shedding of cryptosporidium parvum oocysts in immunodeficient C57BL/6 mice.
    Alak JI; Wolf BW; Mdurvwa EG; Pimentel-Smith GE; Kolavala S; Abdelrahman H; Suppiramaniam V
    Cell Mol Biol (Noisy-le-grand); 1999 Sep; 45(6):855-63. PubMed ID: 10541481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A NMRI suckling mouse model for the evaluation of infectivity of Cryptosporidium parvum oocysts.
    Xunde LI; Brasseur P
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2000; 18(2):94-6. PubMed ID: 12567724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunosuppressed rat model for evaluation of anti-Cryptosporidium activity of sinefungin.
    Brasseur P; Favennec L; Leméteil D; Roussel F; Ballet JJ
    Folia Parasitol (Praha); 1994; 41(1):13-6. PubMed ID: 8050749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of patent gut infections in immunosuppressed adult C57BL/6N mice following intravenous inoculations of Cryptosporidium parvum oocysts.
    Yang S; Healey MC
    J Eukaryot Microbiol; 1994; 41(5):67S. PubMed ID: 7804265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.